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Background: In many countries, low Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) screening rates
among young people in primary-care have encouraged screening programs outside of clinics. Nucleic acid
amplification tests (NAATs) make it possible to screen people in homes with self-collected specimens. We
systematically reviewed the strategies and outcomes of home-based CT/NG screening programs.
Methods: Electronic databases were searched for home-based CT and/or NG screening studies published since
January 2005. Screening information (e.g. target group, recruitment and specimen-collection method) and
quantitative outcomes (e.g. number of participants, tests and positivity) were extracted. The screening programs
were classified into seven groups on the basis of strategies used.
Results: We found 29 eligible papers describing 32 home-based screening programs. In seven outreach programs,
people were approached in their homes: a median of 97% participants provided specimens and 76% were tested
overall (13717 tests). In seven programs, people were invited to receive postal test-kits (PTKs) at their homes: a
median of 37% accepted PTKs, 79% returned specimens and 19% were tested (46225 tests). PTKs were sent along
with invitation letters in five programs: a median of 33% returned specimens and 29% of those invited were tested
(15126 tests). PTKs were requested through the internet or phone without invitations in four programs and a
median of 32% returned specimens (2666 tests). Four programs involved study personnel directly inviting people to
receive PTKs: a median of 46% accepted PTKs, 21% returned specimens and 9.1% were tested (341 tests). PTKs were
picked-up from designated locations in three programs: a total of 6765 kits were picked-up and 1167 (17%)
specimens were returned for screening. Two programs used a combination of above strategies (2395 tests) but the
outcomes were not reported separately. The overall median CT positivity was 3.6% (inter-quartile range: 1.7-7.3%).
Conclusions: A variety of strategies have been used in home-based CT/NG screening programs. The screening
strategies and their feasibility in the local context need to be carefully considered to maximize the effectiveness of
home-based screening programs.
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Chlamydia trachomatis (CT) is the most common noti-
fiable sexually transmissible infection (STI) in the
United States (US) [1], Europe [2] and Australia [3].
Many countries have experienced substantial increase
in reported CT infections over the past decade. Screen-
ing for CT and Neisseria gonorrhoeae (NG) is important
because most infections remain asymptomatic and
often undiagnosed [4,5]. Untreated infections can result
in major sequelae including pelvic inflammatory dis-
ease, ectopic pregnancy, chronic pain, and infertility in
women and epididymitis in men [5].
Clinical guidelines recommend annual CT screening
for sexually active young women in many countries
[6-8], and also sexually active men in some countries [9].
For NG screening, local prevalence and individual risk
factors should be considered [6,8]. Opportunistic screen-
ing of people attending primary-care clinics for non-
sexual health reasons has usually failed to achieve high
coverage [10-12]. This may be due to practitioner re-
ported barriers including lack of knowledge of the bene-
fits of screening, concerns about upsetting patients, time
constraints, lack of reminder systems and little support
for contact tracing [13,14]. Low attendance rates for rou-
tine care among many at-risk people, particularly young
men, also play a role in low screening rates [15-17].
The advent of nucleic acid amplification tests (NAATs)
has made it possible to screen people in homes with
self-collected specimens. Home-based screening, with
urine or self-collected vaginal specimens, has been
shown to be acceptable and has the potential to reach
people who do not get tested otherwise [18]. A recent
review reported that home-based STI screening resulted
in up to 11 times higher testing rates compared to the
clinic-based screening [19]. A randomized control trial
(RCT) showed that 83% of women in a home-based CT
screening arm indicated a preference for future home-
screening compared to 49% in the clinic arm who pre-
ferred future screening in clinics [20]. We conducted a
systematic review of published literature on home-based
CT and NG screening to explore the strategies used for
screening and the key outcomes of screening programs
including participation rates, testing rates, treatment
rates and the positivity.
Methods
This systematic review was conducted according to the
PRISMA guidelines [21].
Search strategy
The electronic bibliographic databases, PubMed and
EMBASE, were searched for English language studies
published between January 1, 2005 and January 28,
2011 with the search terms: Chlamydia, or Chlamydiainfections, or Chlamydia trachomatis, OR Gonorrhea,
AND Screening, or Mass Screening, or testing. The
search was restricted to 2005 onwards, since most pro-
grams involving home-based screening have been
established in recent years. The reference lists of se-
lected studies were screened for other potentially rele-
vant studies.
Inclusion criteria
Papers were reviewed by two authors independently and
disagreements were resolved by discussion and consen-
sus. A study was included if it described a CT or CT and
NG screening program with self-collected specimens at
home and reported the number of tests. For studies in
more than one setting, only home-based screening data
were included. RCTs were included, with the data from
home-testing arm only.
Studies were excluded if: no original data was
reported, such as reviews or editorials; screening was
conducted in both clinics and home but home-screening
data were not reported separately; screening was con-
ducted as part of a cohort study as the testing rates
would be falsely elevated; or screening was anonymous
where the test results could not be provided back to
individuals.
Data extraction and analysis
One author extracted the data from each paper and a
second author verified the data. The following informa-
tion was extracted: demographics; recruitment strategy
(target group, advertisement, reminders); specimens col-
lected; test-kit and specimen delivery method; incentives
provided; number of people invited, participated and
screened; CT/NG positivity; notification of results and
treatment; and the cost of tests (also converted to US
dollars for comparison). The authors were contacted to
collect additional information, if required.
Quantitative outcomes, either extracted or manually
calculated from the raw data, were:
 Participation rate: Number of participants divided by
number of individuals invited × 100
 Specimen return rate: Number of specimens divided
by number of participants × 100
 Testing rate: Number of specimens (number of tests
if not reported) divided by number of individuals
invited × 100
 CT/NG positivity: Number of positive tests divided
by total tests × 100
 Treatment rate: Number of individuals treated
divided by number of positive tests × 100
‘Participants’ were defined as individuals who agreed
to receive home-collection kits or postal test kits (PTKs)
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phone, picked-up PTKs from designated locations, or
completed a questionnaire in screening program.
Programs were classified into seven groups (hereafter
called program type) based on the recruitment strategy,
test-kit and specimen delivery method (Table 1). Pro-
grams were defined as population-based if participants
were randomly selected from listing of all the
individuals (or households) in the target population
(e.g. voter register, telephone directory). For the studies
presenting weighted CT/NG prevalence estimates, the
crude positivity was calculated instead if the required
data were available. A frequency analysis was con-
ducted for all the variables. The median, inter-quartile
range (IQR) and 95% confidence intervals (CI) were
calculated for the rates.
All the analyses were conducted in STATA 12 (StataCorp,
College Station, TX, USA).Results
The initial search led to 3219 unique papers, for which
the titles and abstracts were screened (Figure 1). Full-
text manuscripts were reviewed for 259 papers, of
which 221 were excluded. Of 38 selected, a further
nine papers were excluded as they described the same
programs as other papers [22-30], but any additional
methodology information was extracted. No additional
papers were identified from the reference lists.
A total of 29 papers were included in the review
[31-59]. One paper described a program established in
different settings in two phases [57], the outcomes are
reported separately for both phases due to difference in
the strategies used. For RCTs with more than one home-
testing arm, the data from each arm is presented under
the relevant program type [40,43]. The authors of fourTable 1 Description of program type and specimen collection
Program type Description
Outreach programs Field staff recruited participants at their ho
PTK on invitation
acceptance
People were invited through phone calls and/or let
were sent a PT
PTK along with
invitation
People were sent PTKs along w
PTK with in-person
invitation
People were directly invited to receive
PTK without
invitation
PTKs were requested through the internet or phone
advertisement strategies
PTK with pick-up PTKs were picked-up from designated locations (e
direct invitatio
Multiple strategies A combination of different strategies was used,
separately for each
PTK, postal test kit.papers were contacted to collect additional information
[41,42,54,58].
Overview of programs
Programs involved outreach (n=7), PTKs sent on invita-
tion acceptance (n=7), PTKs sent along with invitations
(n=5), PTKs requested over the internet or phone with-
out invitations (n=4), PTKs offered by in-person invites
(n=4), PTKs picked-up from designated locations (n=3)
and the use of two or more of these strategies (n=2)
(Table 1). Programs were located in Europe (48%), US
(24%), Australia/New Zealand (17%) and other countries
(10%). Most programs (69%) targeted both males and fe-
males. The specimens consisted of urine only (66%), va-
ginal swab only (3%), urine for men and vaginal/vulval
swab or vaginal flush sample for women (31%).
Across all programs, 81633 tests were conducted (me-
dian:550 per program). The overall median participation
rate was 68.9% (n=12) and median specimen return rate
was 51.4% (n=26). The highest median specimen return
rate was in outreach programs (96.5%), followed by pro-
grams providing PTKs on invitation acceptance (78.9%),
PTKs sent along with invitations (32.9%), PTKs re-
quested without invitation (31.8%), PTKs offered in-
person (21.4%), and PTKs picked-up at designated
locations (18.6%). The overall median testing rate was
28.8% (n=19), with a CT positivity of 3.6% (n=27) and
NG positivity of 0.8% (n=7) (Table 2). Eleven studies
reported the treatment rate, with a median of 96%
(range: 67-100%).
Findings by program type
Outreach
There were seven programs with participant recruitment
in homes and immediate collection of specimens. Pro-
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analysis of data (including reviews) (n=11)
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Figure 1 Flow diagram of systematic search strategy.
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population-based (Table 3).
Across these programs, 13717 tests were conducted
(median: 793). The median participation rate was 83.0%
(n=5), with a specimen return rate of 96.5% (n=6) and
testing rate of 76.1% (n=5). The median CT positivity
was 2.0% (n=5) and NG positivity was 0.7% (n=4)
(Table 2). Four programs encouraged participants to
contact the staff for test results [31-34]. One program
reported a 67% treatment rate (n=49), with 24 of 28
traced sexual contacts (86%) also treated [32].
PTK on invitation acceptance
In these seven programs, people were invited to receive
PTKs through phone calls (n=1), letters (n=4), or letters
and phone calls (n=2). Programs were conducted in theUS [43,44], Australia [41], France [39], Denmark [40],
Sweden [42] and the Netherlands [38] (Table 3). Six
population-based programs randomly selected partici-
pants from population, health service or student regis-
ters [38,40,42], telephone directories [41,44], and from a
national survey [39]. Another study was conducted at a
health care plan [43]. In one program, participants re-
quested PTKs through a website after receiving an invi-
tation letter [38]. In this program, in less prevalent
areas, only individuals with risk-scores above a certain
level could request PTKs after mandatory online risk-
assessment [38]. In other programs, people requested a
PTK via phone or by returning prepaid reply cards.
Across these programs, 46225 tests were conducted
(median: 657). The median participation rate was 37.1%
(n=4), specimen return rate was 78.9% (n=5) and testing
Table 2 Summary of home-based screening outcomes by program type
Program type Tests Participation rate Specimen return rate Testing rate CT positivity
Total, median, IQR Median, IQR Median, IQR Median, IQR Median, IQR
Outreach programs 13717, 793, 402-3608 83.0%, 82.3-87.8 96.5%, 91.7-99.4 76.1%, 70.7-82.3 2.0%, 1.5-3.6
(n=7) (n=5) (n=6) (n=5) (n=5)
PTK on invitation acceptance 46225, 657, 105-2580 37.1%, 17.3-65.1 78.9%, 68.3-86.0 18.1%, 12.8-36.2 2.0%, 1.0-4.2
(n=7) (n=4) (n=5) (n=6) (n=7)
PTK along with invitation 15126,1296, 486-4731 32.9%, 28.8-34.8 28.8%, 23.9-28.8 4.6%, 2.6-5.1
(n=5) (n=5) (n=5) (n=5)
PTK without invitation 2666, 709, 279-1055 31.8%, 26.5-47.4 9.1%, 5.2-12.8
(n=4) (n=4) (n=3)
PTK with in-person invitation 341, 37, 5-166 46.4%, 34.7-66.7 21.4%, 19.7-87.5 9.1%, 7.4-58.3 1.5%, 0-9.1
(n=4) (n=3) (n=3) (n=3) (n=3)
PTK with pick-up 1167, 285, 83-799 18.6%, 12.1-20.2 5.4%, 1.8-9.0
(n=3) (n=3) (n=2)
Multiple strategies 2391, 1196, 96-2295 9.2%, 7.3-11.1
(n=2) (n=2)
Overall 81633, 550, 168-1368 68.9%, 40.6-82.6 51.4%, 22.0-87.5 28.8%, 12.8-65.6 3.6%, 1.7-7.3
CT, Chlamydia trachomatis; IQR, inter-quartile range; PTK, postal test kit.
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2.0% (n=7) (Table 2). Reminders were used in four pro-
grams, which accounted for 41% of specimens in one
program (1-5 phone calls, new PTK) [44], 39% of speci-
mens in the second program (two emails) [38] and an
increased specimen return rate from 29% to 68% in the
third program (phone call, two invitation letters, new
PTK) [39]. The fourth program did not report the effect
of reminders (one letter) [43].
Participants were either notified of test results
[39-41,43,44], or could access results online [38,42]. One
program had a 100% treatment rate (n=1) [43], a second
program reported 84% treatment rate (n=36) with 81%
of contacts (n=22) also treated [39], while a third pro-
gram reported 89% treatment rate (n=892) among 43%
of positive individuals who completed a questionnaire
[38]. The cost of one telephone survey and test-kit deliv-
ery was US$250-300 in one program [44], and the cost
of diagnosing one infection was SEK14000 (US$2020) in
another program [42].
PTK sent along with invitation
In these five programs, PTKs were sent to participants’
homes along with invitation letters. Programs were
conducted in the US [43], England [46], Denmark [40],
Estonia [47] and the Netherlands [45] (Table 3). Four
population-based programs randomly selected partici-
pants from the population register [45,47], health ser-
vice register [40] and general practice lists [46], while
another program selected participants from a health-
care plan [43].A total of 15126 tests were conducted (median: 4731).
The median specimen return rate was 32.9% (n=5) and
testing rate was 28.8% (n=5) (Table 2). The median CT
positivity was 4.6% (n=3) (Table 2). Three programs used
reminders, which accounted for 10% of specimens in
one program (letter, phone call, home visit/flagging pa-
tient records) [46], 18% of specimens in the second pro-
gram (letter or new PTK) [45], while the third program
did not report the effect of reminders [43].
Test results were notified to participants in all the
programs. The treatment rate was reported in two
programs, 100% (n=6) in one program [43] and 91%
(n=150) in the second program with 49% of partners
(n=86) also treated [45]. The operational cost of one
program was £14.65 (US$23) per invitation and £21.47
(US$34) per individual screened [46].
PTK without invitation
These four programs in the US [48,50], Australia [51]
and Sweden [49] used internet or telephone to request
PTKs without any direct invitations (Table 3). These
programs used several advertising strategies for promo-
tion. The specimens were returned by post, except one
program which required specimens to be dropped-off in
boxes at selected locations [51]. In one program, in
addition to the internet, PTKs could be picked-up at
community locations but this method was discontinued
due to a poor response rate [48].
A total of 2666 tests were conducted (median: 709)
with the median specimen return rate of 31.8% (n=4).
The median CT positivity was 9.1% (n=3) (Table 2). Test
Table 3 Strategies and outcomes of home-based CT and NG screening studies published between Jan 2005-Jan 2011
classified by program type



















Datta, 2007 [31] US Screening within a national surveyA M/F; 6632 83.0 91.7 76.1 3.6% 0.5%





Randomly selected (national surveyB) M/F; 3608 71.1 99.4 70.7 2.0%
18-44 (69.8-72.3) (99.1-99.7) (69.4-71.9) (1.6-2.5)
Ghebremichael,
2009 [33]
Tanzania Randomly selected households F; 1439 92.1 71.3 65.6 1.5% 0.2%
20-24 (90.9-93.2) (69.2-73.2) (63.6-67.6) (1.0-2.3) (0.0-0.6)
Forhan, 2009
[34]




US Randomly selected households; Monetary
incentives
M/F; 587 87.8 98.3 86.4
15-24 (85.1-90.2) (97.0-99.2) (83.6-88.9)
Adams, 2008
[36]
Barbados Randomly selected (voter’s register) M/F; 402D 82.3% 100 82.3 11.3% 1.8%
18-35 (78.6-85.5) (99.1-100) (78.6-85.5) (8.4-14.9) (0.7-3.6)
Mir, 2009 [37] Pakistan Randomly selected households in a survey M; 256 0.0% 0.8%
16-45 (0.1-2.8)





Participants form population register, PTKs
requested through internet; Reminders
M/F; 41638 20.2 78.9 16.0 4.2%
16-29 (20.1-20.4) (78.6-79.3) (15.8-16.1) (4.0-4.4)
Goulet, 2010
[39]
France Randomly selected (national survey);
Reminders
M/F; 2580 76.3 68.3 52.0 1.7%
18-44 (75.0-77.4) (66.7-69.7) (50.6-53.4) (1.2-2.2)
*Anderson,
2010 [40]
Denmark Randomly selected (county health service
register)




Australia Random household sample (telephone
directory)
F; 657 53.9 E 67.1 36.2E 0.9%
18-35 (51.6-56.2) (64.1-70.0) (33.9-38.4) (0.3-2.0)
Domeika, 2007
[42]
Sweden Randomly selected (population register,
student register); Advertised
M/F; 247 14.5 88.2 12.8 2.0%
19-23 (12.9-16.1) (83.8-91.7) (11.3-14.3) (0.7-4.7)
*Scholes, 2007
[43]
US Participants from enrollees in a managed
care plan; Reminders




US Telephone accessible households;
Monetary incentive; Reminders
M/F; 86 86.0 2.3% 0.0%
18-35 (77.6-92.1) (0.3-8.1)





Randomly selected (civilian registry);
Reminders
M/F; 8383 40.3** 39.9 2.0%
15-29 (39.7-41.0) (39.3-40.6) (1.7-2.3)
Low, 2007 [46] England Randomly selected (general practice lists);
Reminders
M/F; 4731 32.9** 23.9 4.6%
16-39 (32.1-33.7) (23.3-24.5) (4.0-5.3)
*Anderson,
2010 [40]
Denmark Randomly selected (county health service
register)
M/F; 1296 28.8 28.8 6.2%
22-24 (27.5-30.1) (27.5-30.1) (4.9-7.6)
Uuskula, 2008
[47]
Estonia Randomly selected (population registry) M/F; 486 34.8** 28.8 5.1%
18-35 (32.3-37.4) (26.7-31.0) (3.4-7.5)
*Scholes, 2007
[43]
US Participants from enrollees in a managed
care plan; Reminders
M; 230 7.8 (6.9-8.9) 7.8 2.6%
21-25 (6.9-8.9) (1.0-5.6)
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Table 3 Strategies and outcomes of home-based CT and NG screening studies published between Jan 2005-Jan 2011
classified by program type (Continued)
PTKs without invitation programs (n=4)
Gaydos, 2009
[48]
US PTKs requested through the internet;
Advertised
F; 1203 32.4 9.1% 1.3%
>=14 (30.9-33.9) (7.5-10.8) (0.8-2.2)
Novak, 2006
[49]
Sweden PTKs requested through the internet;
Advertised
M/F 906 62.5 5.2%
(59.9-65.0) (3.8-6.8)
Chai, 2010 [50] US PTKs requested through the internet;
Advertised






Australia PTKs requested through the internet/
phone, specimens dropped-off; Advertised
M/F; 45 22.0
16-24 (16.5-28.2)
PTKs with in-person invitation programs (n=4)
Brabin, 2009
[52]
England PTKs offered to women requesting EHC at
pharmacies
F; 264 46.4 19.7 9.1 9.1%
<=24 (44.6-48.3) (17.6-21.9) (8.1-10.2) (5.9-13.2)
Sacks-Davis,
2010 [53]
Australia People at a music festival invited to
receive PTKs; Non-monetary incentive;
Reminders
M/F; 67 34.7 21.4 7.4 1.5%
16-29 (31.6-37.9) (17.0-26.4) (5.4-9.3) (0.0-8.0)
Dabrera, 2010
[54]
England PTKs offered to women requesting EHC at
pharmacies
F; 7 66.7 87.5 58.3
<=21 (34.9-90.1) (47.3-99.7) (27.7-84.8)
Rose, 2010 [55] New
Zealand
PTKs offered to general practice clients to
pass to their social contacts
M/F 3 0.0%
PTKs with pick-up programs (n=3)
Davison, 2007
[56]
Scotland PTKs picked-up from GUM clinic, youth
service, family planning clinic etc.
M/F 799 20.2 9.0%
(18.9-21.5) (7.1-11.2)
MHF, 2005 [57] England PTKs (pick-up) were available to
employees at 6 workplaces; Advertised
M; 285 F 12.1 1.8%
<=30 (10.8-13.5) (0.6-4.0)




Programs with multiple strategies (n=2)
Williamson,
2007 [58]






Australia PTKs requested through internet/phone or




Definitions and abbreviations: Participation rate, participants divided by number invited × 100; Specimen return rate, number of specimens (or tests) divided
by participants × 100; Testing rate, number of specimens divided by number invited × 100. CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; M, Male; F,
Female; US, United States; UK, United Kingdom; PTK, postal test kit; GUM, genitourinary medicine; MHF, Men’s Health Forum.
* Randomized Controlled Trial (RCT) ** calculated among those who received PTKs (excluded undelivered kits).
A National Health and Nutrition Examination Survey (NHANES); B National Survey of Sexual Attitudes and Lifestyles (Natsal); C weighted CT prevalence; D 397 valid
tests; E calculated among 1817 eligible contactable participants after excluding 6555 ineligible and 2629 un-contactable out of 11001 households sampled; F
although the program was targeted at male employees, some of the specimens were returned by female employees; G specimen return rates for individual
locations: Agricultural college, 41.0% (41 tests); Factory, 36.0% (9); Satellite college of university, 14.3% (4); Military Police training center 13.6% (12); Post-16
college 8.3% (17); H 20% of returned kits were distributed from clinics and 10% were picked-up form university.
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grams. The treatment rate in three programs was 97%
(n=105) [48], 99% (n=105) [50] and 100% (n=47) [49].PTK with in-person invitation
Four programs involved study personnel directly invit-
ing people to receive PTKs and were based in England
[52,54], Australia [53] and New Zealand [55] (Table 3).
Two programs were in pharmacies [52,54], one in gen-
eral practice [55] and one at a music festival [53]. A
total of 341 tests were conducted (median: 37). The
median participation rate was 46.4% (n=3), specimen
return rate was 21.4% (n=3) and testing rate was
9.1% (n=3). The median CT positivity was 1.5% (n=3)
(Table 2). SMS reminders were used in one program
[53]. Test results were notified to participants in two
programs [53,55], and one program reported a 92%
treatment rate (n=22) [52].PTK with pick-up
In these three programs, PTKs were available for pick-
up from designated locations [56,57] (Table 3). In the
Men and Chlamydia Project (M&CP) [57], employees of
six workplaces in England picked-up PTKs from boxes
in gents’ toilets, locker rooms and restrooms. The sec-
ond program, an extension of M&CP [57], included five
non-clinical sites. In the third program in Scotland [56],
PTKs were picked-up from the door of a genitourinary
medicine clinic, a youth service, family planning and
other sources.
Across these programs, 1167 tests were conducted
(median: 285). The median specimen return rate was
18.6% (n=3) and the median CT positivity was 5.4%
(n=2) (Table 2). Results were notified to participants in
the M&CP only and the treatment rate was 100% (n=5)
[57]. The cost per test, excluding operational cost, in
M&CP was £8.36 (US$13) and the cost per diagnosed
infection was £695 (US$1079).Multiple strategies
Two programs used more than one strategy for screen-
ing, but did not report the outcomes separately
(Tables 2, 3). In an Australian study [59], PTKs were
picked-up from pharmacies, tertiary education facilities,
community groups and sports clubs, or requested
through the internet and telephone. Only first 100 kits
were analyzed and the treatment rate was 100% (n=7)
[59]. In a Scottish study [58], PTKs were picked-up
from boxes at commercial venues including pharmacies,
young peoples’ drop-ins and record stores, or distrib-
uted at drop-in venues, with 2295 specimens submitted
for screening.Discussion
Home-based CT and NG screening programs have been
conducted in many countries with a range of strategies for
recruitment, test-kit delivery and specimen-collection. A
number of programs were population-based, most used
PTKs and some involved the use of internet for requesting
test-kits. The overall median specimen return rate for
programs included in this review was 51.4%, the me-
dian testing rate was 28.8% and the median CT positivity
was 3.6%.
The key strength of this systematic review is the large
number and range of home-based screening programs
from a number of countries, which allowed examination
of different strategies and outcomes. We used stan-
dardised definitions for the key outcomes to allow com-
parisons within and across program types. However,
there are a few limitations. Firstly, we did not search the
grey literature and thus may not have included other
relevant unpublished programs. Secondly, we were un-
able to report the key outcomes for all programs, such
as participation and testing rates, due to design of the
programs or necessary data not being reported. Thirdly,
any comparison of CT/NG positivity across the pro-
grams is limited by different target populations studied
and known prevalence in the underlying populations.
This review included a number of outreach pro-
grams. The high specimen return rates in these pro-
grams indicate that majority of people agreed to
provide specimens when approached in their homes.
In these programs, specimen-collection was integrated
into ongoing national [31,32,34] and population-based
surveys [33,35-37], and hence incurred no significant
additional cost and human resources. The downside of
this approach is that such surveys are often conducted
infrequently and are therefore more suitable for esti-
mating the prevalence than being a method for on-
going screening.
The use of mailed specimens appears to have in-
creased in popularity in recent years as most programs
in this review used PTKs for screening. The recruitment
strategies in these programs have varied considerably.
Programs with PTKs mailed alongside an invitation have
been implemented in a few European countries, but the
specimen return rates were low. Programs which sent
PTKs on invitation acceptance, on the other hand, were
associated with relatively higher specimen return rates.
Some PTK programs required the test-kits to be col-
lected or offered at specific physical locations. These
were associated with relatively less people being tested
as well as low specimen return rates.
A few PTK programs in the review required the test-kits
to be requested through the internet. PTKs requested in
this way appear to be a logistically feasible strategy for
establishing large population-based screening programs,
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Netherlands [38]. The three year results of this register-
based yearly CT screening program published recently
demonstrate no significant decrease in CT positivity in
the target population after three screening rounds, with
the testing rates declining in each round [60]. However,
among people who were screened in all three years, the
positivity dropped from 5.9% to 2.9% [60]. The number of
individuals screened in the first round (n=41638) was
greater than in any other program in the review [38]. The
internet can be useful for selective screening of high-risk
people through the completion of online risk-assessment
questionnaires, as done in less CT prevalent areas in the
Netherlands [38]. Other internet programs in the review
did not involve direct invitations and relied on people ac-
tively seeking PTKs after programs were advertised
[48-50]. Relatively few people were tested by this approach
but CT positivity was higher, which may be due to people
self-selecting on the basis of their risk. The internet also
provides an opportunity to deliver test results online in
a confidential manner at the individual’s convenience
[38,42,49].
The use of reminders has shown to improve the speci-
men return rates [38,39,44-46]. However, reminder im-
plementation on a large scale, along with notification of
results and contact-tracing, can be resource intensive
[61] and may require comprehensive registries. There
may be other logistic challenges in establishing PTK pro-
grams, such as collection and transport of specimens.
Clinical specimens must comply with international and
national packaging requirements for transport [62]. The
current three-layered packaging system for infectious
substances often results in large packages (at least one
surface with minimum 100×100mm dimension) [63],
which may require delivery and collection at the post-
office or through a courier, and thus costly to transport
[62]. However, a recently developed sponge-based urine-
collection device called UriSwab (Copan Diagnostics,
Inc.) holds a small amount of urine after being held in
the urine flow or dipped in a specimen cup. UriSwab is
easy to transport, has shown good performance in
detecting CT/NG infections and can potentially facilitate
the establishment of PTK programs [64]. Other consid-
erations in home-based screening programs may include
the issues of privacy and confidentiality, such as ensur-
ing communication of results, treatment and contact tra-
cing in a confidential manner and in-line with the
individual’s preference [61,62].
Home-based testing can potentially reduce individual
screening costs by avoiding clinic fees as well as the in-
direct costs, such as time off work and transportation
[65]. However, there is no conclusive evidence of the
cost-effectiveness of home-based screening over routine
clinic-based screening. Four programs in this reviewprovided cost information in association with home-
based screening [42,44,46,57]. Only Low and colleagues
reported full operational cost of a PTK screening pro-
gram [46], while Domeika et al. compared the cost of
home-based screening in their study with routine
screening and reported the former to be about five times
higher [42]. One RCT compared the cost of home and
clinic-based screening and found that home-screening
provided a cost-saving ($25 per test in home vs. $111 in
clinic after including direct and indirect costs) [65], but
that the cost-saving was not seen when the results were
restricted to asymptomatic tests. It is thus important for
future programs to focus on estimating operational costs
in relation to the screening outcomes to establish the
cost-effectiveness of home-based screening.
Conclusions
This systematic review shows that home-based screen-
ing programs have been conducted in various countries
and have utilised a variety of strategies. Home-based
testing with self-collected specimens appears to be an
acceptable and logistically feasible method for CT and
NG screening outside of clinics. However, economic
evaluation of large-scale home screening programs
is warranted to assess their cost-effectiveness in the
real-world scenario. The recruitment and specimen-
collection strategies adopted for home-based screening
and their potential impact on the outcomes need to be
carefully considered. A pilot program to assess the
feasibility of screening in the local context would
be highly recommended before embarking on a large-
scale program. Ongoing assessment of the outcomes
and subsequent modification of strategies should be
considered to improve the effectiveness of screening
programs.
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